SubsidieMeestersRevolutionising allergies diagnostics with the next generation of ultra-sensitive highly multiplexed diagnostic tests based on micro-pearls
Nexdot is developing a groundbreaking diagnostic test using fluorescent µpearls to simultaneously assay IgE for 500+ allergens from a single drop of blood, significantly reducing diagnostic time and costs.
Projectdetails
Introduction
The WHO predicts that half of the European population will suffer from allergies. Allergies are a growing burden for our society, our healthcare system, and companies that have to take staff off work due to disabling symptoms.
Innovation in Allergy Testing
Thanks to fluorescent µpearls and the discovery of Quantum Plates, Nexdot is developing a highly multiplexed diagnostic test that will allow the assay of IgE on 500 allergens (and up to 1000) at once using only one drop of blood.
This innovation will revolutionize the way allergies are treated by drastically reducing the time to diagnosis and its associated cost, achieving a reduction of 10 to 20 times.
Potential Extensions of Technology
Our technology could also be extended to serology tests for the detection of patients' antibodies against infectious agents or cancer markers.
Additionally, it can be adapted for global health applications, enabling easy and cost-effective detection of:
- Antigens as infectious agents
- Toxic agents in humans, animals, or the environment
- Food safety for the industry
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 3.628.125 |
Tijdlijn
| Startdatum | 1-5-2023 |
| Einddatum | 31-10-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- NEXDOTpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Transforming Molecular Diagnostics through NanoTechnologyAltratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
Transforming Molecular Diagnostics through NanoTechnology
Altratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnosticsPRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries. | ERC Proof of... | € 150.000 | 2023 | Details |
Snelle SOA resistentie diagnostiekHet project ontwikkelt innovatieve DNA-tests voor de snelle detectie van antibiotica-resistentie bij Neisseria gonorrhoeae en Mycoplasma genitalium om effectieve behandeling van SOA's te waarborgen. | Mkb-innovati... | € 164.783 | 2017 | Details |
ECL-based Infectious Pathogen (bio)SEnsorECLIPSE aims to develop a portable, cost-effective platform using ultrasensitive detection methods for rapid identification of infectious pathogens, enhancing response to future pandemics. | EIC Pathfinder | € 2.683.996 | 2022 | Details |
HYDROGELPARELS ALS 3D NANOFILTRATIESYSTEEM VOOR DE CONCENTRATIE VAN KANKER BIOMARKERS IN URINEQurin Dx ontwikkelt een point-of-care urine test met hydrogelparels voor vroege kankeropsoring, waardoor directe detectie mogelijk is zonder laboratoriumwachttijden. | Mkb-innovati... | € 322.531 | 2021 | Details |
Enzyme-Linked DNA Displacement (ELIDIS) Assay as an innovative immunoassay platformDevelop and validate a novel immunoassay, ELIDIS, as a portable, efficient alternative to ELISA for biotech and biopharma applications, enhancing accessibility and ease of use. | ERC Proof of... | € 150.000 | 2024 | Details |
self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnostics
PRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries.
Snelle SOA resistentie diagnostiek
Het project ontwikkelt innovatieve DNA-tests voor de snelle detectie van antibiotica-resistentie bij Neisseria gonorrhoeae en Mycoplasma genitalium om effectieve behandeling van SOA's te waarborgen.
ECL-based Infectious Pathogen (bio)SEnsor
ECLIPSE aims to develop a portable, cost-effective platform using ultrasensitive detection methods for rapid identification of infectious pathogens, enhancing response to future pandemics.
HYDROGELPARELS ALS 3D NANOFILTRATIESYSTEEM VOOR DE CONCENTRATIE VAN KANKER BIOMARKERS IN URINE
Qurin Dx ontwikkelt een point-of-care urine test met hydrogelparels voor vroege kankeropsoring, waardoor directe detectie mogelijk is zonder laboratoriumwachttijden.
Enzyme-Linked DNA Displacement (ELIDIS) Assay as an innovative immunoassay platform
Develop and validate a novel immunoassay, ELIDIS, as a portable, efficient alternative to ELISA for biotech and biopharma applications, enhancing accessibility and ease of use.